Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
- Conditions
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 140
- Registration Number
- NCT04259944
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
🇮🇹Ospedale Policlinico San Martino IRCCS, Genova, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 760
- Registration Number
- NCT04258163
- Locations
- 🇨🇳
First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 108
- Registration Number
- NCT04250948
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
- Conditions
- Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Pathologic Stage IV Gastric Cancer AJCC v8Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Metastatic Esophageal AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 314
- Registration Number
- NCT04248452
- Locations
- 🇺🇸
Mercy Cancer Center-West Lakes, Clive, Iowa, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 264
- Registration Number
- NCT04247984
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 83
- Registration Number
- NCT04245865
- Locations
- 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Conditions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT04220203
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 23
- Registration Number
- NCT04202978
- Locations
- 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 155
- Registration Number
- NCT04198727
- Locations
- 🇲🇨
Hôpital Princesse Grâce, Monaco, Monaco
🇫🇷Clinique Saint Jean, Cagnes-sur-Mer, France
🇫🇷Centre Antoine Lacassagne, Nice, France
The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 410
- Registration Number
- NCT04185649
- Locations
- 🇨🇳
Beijing Shijitan Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.